BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 177
- Registration Number
- NCT04643470
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
- Conditions
- B-cell Malignancies
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04551963
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺John Flynn Private Hospital, Tugun, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 181
- Registration Number
- NCT04551898
- Locations
- 🇺🇸
Btc Network Midland Florida Clinical Research Center, DeLand, Florida, United States
🇺🇸Elixia Clinical Research Collaborative, Hollywood, Florida, United States
🇧🇷Consultoria Medica E Pesquisa Clinica, Sorcaba, Brazil
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 18
- Registration Number
- NCT04532294
- Locations
- 🇦🇺
Q PHARM, Herston, Queensland, Australia
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Drug: Salvage Chemotherapy
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 123
- Registration Number
- NCT04486391
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Quanzhou First Affliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04472650
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 13
- Registration Number
- NCT04470908
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 66
- Registration Number
- NCT04436107
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 64
- Registration Number
- NCT04401800
- Locations
- 🇨🇳
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
- Conditions
- COVID-19COVID-19 Pulmonary Complications
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT04382586
- Locations
- 🇺🇸
St Jude Medical Center, Fullerton, California, United States
🇺🇸Medstar Heath Research Institute Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸John D Archbold Memorial Hospital, Thomasville, Georgia, United States